Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
322.83
+4.58 (1.44%)
At close: Jun 27, 2025, 4:00 PM
322.83
0.00 (0.00%)
After-hours: Jun 27, 2025, 5:59 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 23 professional analysts, the 12-month price target for Alnylam Pharmaceuticals stock ranges from a low of $220 to a high of $500. The average analyst price target of $335.74 forecasts a 4.00% increase in the stock price over the next year.
Price Target: $335.74 (+4.00%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 11 | 11 | 12 | 12 |
| Buy | 8 | 8 | 9 | 9 | 9 | 8 |
| Hold | 5 | 4 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 23 | 24 | 24 | 25 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $320 → $377 | Strong Buy | Maintains | $320 → $377 | +16.78% | Jun 26, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $300 → $360 | Buy | Maintains | $300 → $360 | +11.51% | Jun 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $330 → $338 | Buy | Maintains | $330 → $338 | +4.70% | Jun 12, 2025 |
| UBS | UBS | Strong Buy Maintains $331 → $349 | Strong Buy | Maintains | $331 → $349 | +8.11% | May 2, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $300 → $325 | Strong Buy | Maintains | $300 → $325 | +0.67% | May 2, 2025 |
Financial Forecast
Revenue This Year
2.94B
from 2.25B
Increased by 30.77%
Revenue Next Year
3.84B
from 2.94B
Increased by 30.51%
EPS This Year
-1.38
from -2.18
EPS Next Year
0.95
from -1.38
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.2B | 5.9B | 6.9B | ||
| Avg | 2.9B | 3.8B | 4.9B | ||
| Low | 2.4B | 2.8B | 3.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 44.4% | 100.7% | 80.9% | ||
| Avg | 30.8% | 30.5% | 26.7% | ||
| Low | 7.9% | -6.2% | -8.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.45 | 4.84 | 9.32 | ||
| Avg | -1.38 | 0.95 | 5.56 | ||
| Low | -2.29 | -3.11 | 1.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 881.9% | ||
| Avg | - | - | 485.8% | ||
| Low | - | - | 55.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.